$ Value
—
Shares
116,693
Price
—
Filed
Feb 9
Insider
Name
Atlas Venture Fund X, L.P.
Title
—
CIK
0001628098
Roles
Transaction Details
Transaction Date
2026-02-09
Code
U
Table
Non-Derivative
Ownership
Indirect
Equity Swap
No
Shares After
—
Footnotes
Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"), | (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. | The shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. | The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, LP ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any. | The shares are held directly by AVAO I LP. AVAO I LLC is the general partner of AVAO I LP. AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVAO I LP except to the extent of its pecuniary interest therein, if any.
Filing Info
Atlas Venture Fund X, L.P.'s History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-02-09 | GBIO | U | — |
| 2026-02-09 | GBIO | U | — |
| 2026-02-09 | GBIO | U | — |
Other Insiders at GBIO (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
| JONAS JEFFREY M | — | — | 2026-02-09 |
| Rowland Charles A Jr | — | — | 2026-02-09 |
| Christensen Gustav | — | — | 2026-02-09 |
| Quinn Anthony G. | — | — | 2026-02-09 |
| Rhodes Jason P | — | — | 2026-02-09 |
| Atlas Venture Fund X, L.P. | — | — | 2026-02-09 |
| Cooper Ronald Harold Wilfred | — | — | 2026-02-09 |
| Stehman-Breen Catherine | — | — | 2026-02-09 |
| MCDONOUGH GEOFF | — | — | 2026-02-09 |
| Nicholson Donald William | — | — | 2026-02-09 |
|
Howze Yalonda
INTERIM CEO & PRESIDENT
|
— | — | 2026-02-02 |
|
Howze Yalonda
INTERIM CEO AND PRESIDENT
|
— | — | 2026-02-09 |
| Appelhans Dannielle | — | — | 2026-02-09 |
|
Conway Kevin John
CHIEF FINANCIAL OFFICER
|
— | — | 2026-02-09 |
|
Conway Kevin John
Chief Financial Officer
|
— | — | 2026-02-02 |